. Author manuscript; available in PMC: 2019 Feb 15.

Published in final edited form as: Cancer. 2017 Dec 6;124(4):688–697. doi: 10.1002/cncr.30967

Table 5.

Univariate Analysis of Progression-Free and Overall Survival among Eligible and Treated Patients

		PFS in months Median (95% CI)	OS in months Median (95% CI)	P-value Log-rank
All patients		10 (9–12)	22 (20–29)	PFS	OS
High TS	Arm A IROX/Bev	10 (6–11)	18 (14–23)	A vs B 0.41 B vs C 0.04	A vs B 0.15 B vs C 0.07
High TS	Arm B FOLFOX/Bev	9 (8–11)	21 (16–32)
TS Low	Arm C FOLFOX/Bev	13 (10–14)	32 (23–44)

TS = thymidylate synthase; IROX = irinotecan and oxaliplatin; Bev = bevacizumab; FOLFOX = folinic acid (leucovorin), 5-Fluorouracil, and oxaliplatin; CI = confidence interval. The TS-Low cohort includes both TS-Low and TS-indeterminate expression